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John F CarpenterThe development (“D” in “R&D”) component for thera-
peutic protein products includes efforts to understand
and improve bioprocessing methods (e.g., filling pump
operation for vials and syringes, freeze-drying to create
more stable product), product degradation pathways,
and rational means to improve protein stability, new
analytical methods, drug delivery methods, and investi-
gation of key product parameters affecting product
safety and efficacy. Research in these areas occurs in
pharmaceutical companies and in universities. Often in
companies, the focus is on doing the work that is needed
to get a given product into clinical trials and on the
market, whereas in universities, the focus is usually on
more fundamental, mechanistic understanding of key
issues such as factors causing protein aggregation and
how to characterize and minimize this type of degradation.
Therefore, there are numerous natural, synergistic collabo-
rations between pharmaceutical companies and academic
researchers, which provide for more rapid advancement of
the field and relevant education of students than if the two
groups worked independently. There is a long tradition of
such productive and valuable collaborations between
industry scientists and professors in pharmaceutical
sciences departments. For this commentary, based on
my two decades of experience with such collaborations, I
will describe my views on the advantages of such partner-
ships and some of the pitfalls.
To start with, it is important to emphasize that a
productive academic lab can rarely function and thrive
on industry funding alone. There is also a need for
funding from foundations or federal agencies to broaden
the scope of the work in the lab, as well as to provideCorrespondence: John.Carpenter@ucdenver.edu
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reproduction in any medium, provided the ormore long-term financial support for the lab. Typically,
pharmaceutical companies will commit informally to
funding a given project for at least a few years, i.e., for
the duration of the research for a thesis project. How-
ever, often the formal collaborative research agreement
will cover 1 year, with the anticipation that the project
will be renewed annually. On the other hand, usually the
project is “pre-approved” before the formal project
proposal is sent to the company. This situation arises
because the company researchers initiate the discussion
about a funded collaboration by contacting the professor
about a research project area. During these discussions,
the groups work together to formulate a mutually agree-
able outline for the project, with the understanding that
funding should be available from the company. Then, it
is just a matter of putting together a few pages of the
technical proposal and a budget and letting the contract
negotiators for the respective organizations start their
work (see below for more on some issues with contracts).
Recently, however, many companies have had changes in
management philosophy and budgeting approaches for
outside collaborations that may necessitate review of
proposals by a company committee. In some cases, this
committee has simply to approve the overall scientific
aspects of the project and the perceived value to the
company. However, in other cases, such committees must
rank order the proposals, with only the top ones getting
funding. Therefore, prior to entering into serious discus-
sions with a company about a potential collaborative
funded project, it is critically important to understand
exactly how that company handles project proposals and
decisions for funding, including the timing for evaluation
of a proposal and funding decisions.
Because funding from pharmaceutical companies can
be a valuable source of support for university investiga-
tors, new faculty often asks how they can obtain this sort. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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based on peer-reviewed papers they have read of yours
in areas of interest. Occasionally, the initial contact from
company scientists can occur at a conference when the
university lab is presenting the newest work. The key
point is that most often, the company seeks out the
professor rather than putting out some general call for
proposals. This is an important issue to consider in the
evaluation of faculty. In some departments, funding
from the industry used to be viewed as somehow second
class compared to grants from federal or foundation
sources. However, most academics now realize that indus-
try funding is actually a sign of success and recognition in
the field; otherwise, companies would not approach a
professor about a collaborative project.
It is also important to emphasize that industrial collabo-
rations have tremendous value to the university missions
of research and education, well beyond the provision of
funding for a lab or a program.
1. The collaborations allow both groups to work on
new areas of critical importance to the advancement
of the drug development field and human medicine.
If the project did not meet these criteria, a
pharmaceutical company would probably not fund it.
2. Professors and students (also including postdoctoral
researchers) get an opportunity to work closely with
outstanding scientists in the industry. The
contributions of the industry scientists to the
fundamental and theoretical aspects of a project are
often important. Furthermore, their practical insights
into key pharmaceutical development questions can
help shape a project such that, in addition to advancing
basic knowledge, the work can have immediate impact
on current drug development problems in the field.
Furthermore, industry scientists mentor the students
and help them to prepare for a career in a
pharmaceutical company or a university.
3. Students on the project may get to spend time
working in the labs of the sponsoring pharmaceutical
company, which is of great value in their training both
for scientific growth and increasing understanding of
the industrial research environment. In some cases,
the industry lab will have instruments and/or
processing equipment that are not available in
universities, providing the student with unique
opportunities in a research project. Also, the students
get to participate in a truly multidisciplinary research
with experts in areas such as pharmaceutical sciences,
analytical chemistry, regulatory affairs, immunology,
and chemical engineering.
4. For our specific area of research, the therapeutic
proteins provided by the collaborating company are
invaluable for several reasons. Obtaining gramquantities of highly purified protein(s) is obviously
much preferred to the costs and time of expressing
and purifying a protein in the university. Also, work
on real drug development problems is not of nearly
as much value if some model nondrug protein
(e.g., lysozyme) is used. Moreover, industry scientists
will often already have worked out the key
degradation routes for a given protein and many of
the appropriate analytical methods.
5. Many times, companies will bring to the attention of
an academic researcher a new emerging problem
facing the industry. For example, we were
approached by a company that found specific types
of filling pumps causing formation of visible particles
in a monoclonal antibody product. Published
research on filling pump-induced damage was
unheard of at the time, and university labs were not
focusing on this area. As a result of the collaboration,
we established filling pump studies in the university
lab that led to new mechanistic insights into particle
generation, successful thesis projects, and
publications. More recently, the problems associated
with protein aggregation caused by silicone oil in
prefilled syringes were brought to our attention by
several industrial collaborators, each of whom was
interesting in different mechanistic aspects of the
process and rational routes to inhibit it. As result,
new understanding was obtained, a few different
thesis projects were funded, and several research
papers were published.
6. Students learn the critically important context for
their research and get plenty of attention at
conferences, as well as job offers from the industry.
7. With time, some of these students work their way
into positions in pharmaceutical companies such that
they can collaborate with (and fund) their former
thesis advisor on projects.
8. By working collaboratively, industry and academic
researchers can solve real problems and quickly lead
to improvements in the speed and efficiency of drug
product development and to greater safety and
efficacy of these products. Such results improve
medical care and reduce costs of medicines.
Of course, there are also potential pitfalls with collab-
orative, sponsored projects with industry. However, with
insight into the key issues, these can usually be avoided.
1. First and foremost, it is absolutely essential that there
is a specific language in the sponsored research
agreement stating that the results of the research can
be presented at conferences and published. Often,
the company will have a provision that requires that
abstracts, conference presentations, and manuscripts
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potential patents or proprietary information) prior to
submission. This requirement means that the
academic lab must plan well in advance of
conferences to have the abstract, and then the
presentation, completed. If the company decides that
something is patentable in the results, then public
disclosure of the work could be delayed. This does
not have to be too long; patent applications can be
prepared relatively rapidly. However, on rare
occasions, presentation of a student’s research at a
conference has been blocked because of a patent
application. Of course, the student can then present
the work at a later conference.
2. Companies (and their lawyers!) do not like to have
information made public about drug products
currently in development. Therefore, it is helpful if
the research is going to focus on a therapeutic
protein provided by the company and a protein that
is no longer being developed is chosen, e.g., a protein
that did not progress in clinical trials. For
publication, the name, and perhaps sequence, of the
protein drug may be required by the journal, but
there are exceptions. For example, many therapeutic
proteins are monoclonal antibodies. When these are
used as model proteins in studies, it may not be
necessary to disclose the name or sequence in a
research publication.
3. The ownership of any inventions (or other
intellectual property) will also be an important point
of discussion during the contract negotiations. In my
experience, no matter what the starting points of the
university and the company, the negotiations lead to
the same conclusion in the contract. The language
states that if only university researchers are
inventors, then the invention belongs to the
university and the company can have first rights to
negotiate a license to the invention. If the inventors
are only company employees, then the company
owns the invention. If, however, both university and
company employees are inventors (which is often the
case when a project actually leads to an invention),
then each side can use the technology, with the
understanding that the company also could negotiate
to obtain exclusive rights to the university's
ownership claim.
Nowadays, most university contract and technology
transfer offices are well experienced in such
negotiations. Thus, the faculty member does not
need to get involved in these affairs. However, in
some instances, the sort of intellectual property
terms described above cannot be agreed upon, and
the faculty member's input may be needed. If the
company wants more ownership rights than istypical but the work is of critical importance for the
university lab, the faculty member may be able to
push for the contract to be completed, but of course,
these issues vary on a case-by-case basis.
4. Company priorities and/or personnel can change, so
a project that was informally anticipated to run for at
least a few years may be not be renewed after a given
year of funding. Also, as profitability of drug
companies decreases, the management may decide
that it can't afford to fund external projects. In these
cases, hopefully, other funding sources (e.g., federal
grants or bridging funds from the university) will be
available to support the affected student.
Overall, the advantages of collaborations with the
pharmaceutical industry far outweigh the potential pit-
falls for university researchers. In addition to supporting
sponsored research agreements between professors' labs
and companies, it is important for universities to pursue
larger, long-term collaborations with pharmaceutical
companies. University faculty and administrators should
appreciate the value of all of these types of collabora-
tions in the furtherance of the education and research
missions of the university and to advancing medicine.
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